Dexpramipexole dihydrochloride Catalog No.:M9926-2 including T315I

including T315I

mimics the neuroprotective mechanisms of basic fibroblast growth factor

2017 Jan 6

Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity

ZLN024 directly activates recombinant AMPK α1β1γ1 and its homologue α2β1γ1 in a concentration-dependent manner

Dexpramipexole dihydrochloride Catalog No.:M9926-2 including T315IDexpramipexole, also known as KNS 760704 and (R) Pramipexole, is under development for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease. The drug failed to show efficacy in terms of function or survival in a Phase III study of patients with ALS. Dexpramipexole is a low molecular weight, water soluble, orally bioavailable, renally excreted compound with linear pharmacokinetics, and has been shown to be well